Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Traws Pharma, Inc. TRAW

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.8M
▲ 1134.5% YoY
$9.2M
$-20.8M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 2.8M
Revenue, FY2025 · full 15-year series below
Revenue $M Net income $M
FY2025 · Revenue 2.8 · Net income 9.2
20M40M-100M-200M
201120142017202020232025
Compound annual growth
+131.1%
+64.6%
−13.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +64.6% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

329 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating -640.7% · Net 328.7%
-20000%-40000%-60000%
201120182025
ROE
FY2023 · ROE -97.2%
-100%-200%
201120182025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -20.8
-25.0M-50.0M
201120182025

Total assetsUSD 10.6M
CashUSD 3.8M
Current ratio0.72×

Not available: we don't have the total debt figure for this period.

The 15-year record

15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
TRAW, 15-year financial record
Metric 202520242023202220212020201920182017201620152014201320122011
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.1−0.0−0.0
EBITDA $B−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.1−0.0−0.0
Income tax $B◌◌◌◌◌0.00.0−0.00.00.00.00.00.0◌◌
Net income $B0.0−0.2−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.1−0.0−0.0
Free cash flow $B−0.0−0.0−0.0◌◌−0.0−0.0◌◌◌◌−0.1−0.10.0−0.0
EPS, diluted $0.82−35.21−22.57−0.91−0.96−2.17−1.49−4.99−40.15−4.44−10.54−2.94−6.12−15.35−14.18
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————
ROE %——−97.2−51.0−61.8−283.5−253.6——−274.9−146.4−123.5———
Shares out B0.010.000.020.020.020.190.110.010.010.010.030.020.020.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 58 reconciliationsAUDITED

Reconciled in 15 of the 15 fiscal years we could check. 10 checks were skipped: the balance sheet is not tagged before 2012. Four checks were skipped: EPS is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2011

Share this section

Download image